Saeedeh Farajzadeh; Mahin Aflatoonian; Morvarid Amirmijani; Zahra Farahmandinia; Rezvan Amiri; Maryam Khalili
Abstract
Background: Complications of chemotherapy most commonly involve highly proliferative cells, including the skin and its appendages and mucosa. This study evaluated mucocutaneous complications of chemotherapy in children with cancer.Methods: This descriptive cross-sectional study involved 92 children who ...
Read More
Background: Complications of chemotherapy most commonly involve highly proliferative cells, including the skin and its appendages and mucosa. This study evaluated mucocutaneous complications of chemotherapy in children with cancer.Methods: This descriptive cross-sectional study involved 92 children who received chemotherapy at the Pediatric Oncology Ward of Afzalipour Hospital, Kerman, Iran, between September 2018 and March 2019. Demographic and clinical features of the patients were collected by history, physical examination, and laboratory tests (biopsy, fungal and bacterial smears if necessary). Frequency and percentage were used for qualitative analysis. Mean ± standard deviation was used for quantitative analysis.Results: The mean age of patients was 6.60 ± 3.70 years (range 1 to 16 years). More than half of the patients (55.4%) were males. The most common malignancy was acute lymphocytic lymphoma (ALL). More than half of the children (60%) had mucocutaneous complications due to chemotherapy; these were significantly more common in boys than girls (70.6% vs. 48.8%). The mean age of children with mucocutaneous complications (7.41 ± 3.98) was significantly higher than those without complications (5.33 ± 2.84). The most common mucocutaneous side effects were, in order, alopecia, mucositis, and skin infections.Conclusion: We found that side effects of chemotherapy weresignificantly more common in older children, boys, and childrenwith leukemia. Vincristine was the most common culprit.
Leila I Izadi Firouzabadi; Hamidreza Mahmoudi; Ali Khamesipour; Abhay Satoskar; Alireza Firooz
Abstract
Background: Basal cell carcinoma (BCC) is the most common type of skin malignancy. Hyperthermia is used as adjuvant therapy together with radiotherapy and chemotherapy in the treatment of some cancers. This study aimed to evaluate the efficacy and safety of thermotherapy in the treatment of BCCs.
Methods: ...
Read More
Background: Basal cell carcinoma (BCC) is the most common type of skin malignancy. Hyperthermia is used as adjuvant therapy together with radiotherapy and chemotherapy in the treatment of some cancers. This study aimed to evaluate the efficacy and safety of thermotherapy in the treatment of BCCs.
Methods: This pilot trial was carried out on five patients with nodular or superficial BCCs on the scalp and face.Thermotherapy was done at 50° C for a duration of 30 seconds with a radiofrequency device (Thermomed 1.8 thermosurgery technologies). Thermotherapy treatment was applied only in one session. The first follow-up was one week after the procedure and then every month for six months. The last follow-up was one year after the procedure.
Results: All patients showed clearance of the tumors. Blisters, ulcers, crusts, and necrosis were the side effects, which healed with acceptable degrees of scarring. No recurrence was observed at the end of the study.
Conclusion: Thermotherapy was safe and efficacious for the treatment of BCCs on the scalp and face. It should be considered especially for the low-risk subtypes of this cancer.
M Shahidi Dadras; L Ataei
Volume 4, Issue 2 , 2001, , Pages 21-25
Abstract
Background: Mycosis fungoides (MF) is a cutaneous T cell lymphoma. There are only palliative treatments in advanced stages with no cure. Most chemotherapy regimens have temporary effects with various side effects. Objective: The objective of this study was to assess the efficacy of a new chemotherapy ...
Read More
Background: Mycosis fungoides (MF) is a cutaneous T cell lymphoma. There are only palliative treatments in advanced stages with no cure. Most chemotherapy regimens have temporary effects with various side effects. Objective: The objective of this study was to assess the efficacy of a new chemotherapy regimens in advanced stages of MF. This regimens takes advantage of synergistic effect of methotrexate and fluorouracil and also uses leucovorin to reduce side effects of methotrexate. Patients and Methods: Five patients with advanced stages of MF (Stage IIB and higher) were treated with several courses of this chemotherapy regimens in a quasi experimental study. Results: Four patients responded partially one responded completely to this regimen but all of them relapsed after tapering the treatment. All of them tolerated the drugs well and no serious side effects were observed. Tumoral lesions showed better response. Conclusion: Although this chemotherapy regimen, similar to other regimens, only had temporary and palliative effects, it was tolerated well without serious side effects.